Bank of America’s Astria Therapeutics ATXS Stock Holding History

Bank of America’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-6,000	Closed	-$32K	–	8385
2025 Q1	$32K	Hold	6,000	–	–	﹤0.01%	6852
2024 Q4	$53.6K	Hold	6,000	–	–	﹤0.01%	6612
2024 Q3	$66.1K	Buy	+6,000	New	+$66.7K	﹤0.01%	6472

Bank of America's ATXS Position: Q1 2026 in Review

Bank of America sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 83,041 shares — an estimated $1.09M sold.

Bank of America first reported a position in ATXS in Q3 2015 and held it in 36 quarters. The position peaked at $1.54M in Q1 2024. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

Bank of America reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
Bank of America sold 83,041 Astria Therapeutics shares in Q1 2026, an estimated $1.09M.
Bank of America first reported a position in Astria Therapeutics in Q3 2015 and held it in 36 quarters.
Bank of America's Astria Therapeutics position peaked at $1.54M in Q1 2024.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.